Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Stemline Therapeutics Doubled Overnight

By Brian Orelli, PhD – May 4, 2020 at 12:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ultimate binary event caused the biotech's shares to jump.

What happened

Shares of Stemline Therapeutics (STML) are up 153% to $12.02 at 1:11 p.m. EDT after the company announced it is being acquired by a privately held Italian pharmaceutical company, Menarini. Investors will get $11.50 per share when the deal closes and a contingent value right that will pay an additional $1 per share when Stemline's Elzonris is sold in any of the EU5 countries: France, Germany, Italy, Spain, or the U.K.

So what

Stemline launched Elzonris last January for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a fairly rare type of cancer -- there were only 534 patients identified in the U.S. in 2018 -- and sales of Elzonris have been lackluster, coming in at just $11.8 million in the fourth quarter of 2019.

Fortunately Elzonris has potential beyond BPDCN because it targets CD123, a protein involved in many blood cancers. Stemline is currently testing the drug in patients with chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia, the potential for which justifies Menarini's willingness to pay double what investors were valuing Stemline at on Friday.

Business men shaking hands.

Image source: Getty Images.

Now what

With shares trading higher than the $11.50 base acquisition price, investors are clearly betting there's a good chance that Elzonris is approved by EU regulators by the Dec. 31, 2021 deadline and eventually sold in the EU5, triggering the additional $1-per-share payment. The marketing application in Europe is already under review, so the deadline appears well within reach as long as regulators don't request any additional clinical trial data.

The transaction is expected to close this quarter.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Stemline Therapeutics, Inc. Stock Quote
Stemline Therapeutics, Inc.
STML

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.